Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

IPN10200

Phase 2Biologic

IPN10200 is one of 14 biologic programs targeting Cervical Dystonia. It is currently in Phase 2.

3

Indications

6

Total Trials

6

Active Trials

13

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaRecruiting

SpasticityRecruiting

Episodic MigraineActive, not recruiting

Cervical DystoniaPhase 2

Recruiting

SpasticityPhase 2

Recruiting

Episodic MigrainePhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Spasticity

#DrugCompanyPhaseTrials

Lioresal

Namenda

Cesamet

BBausch Health Americas, Inc.

Zanaflex

LLegacy Health System

Dysport

IPN10200

Corabotase

Botulinum Neurotoxin Type a

DDeNova Research

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Moderate to Severe Glabellar Lines

NCT07427797

PreclinicalActive, not recruiting

Moderate to Severe Upper Facial Lines

NCT04821089

Q4 2027

Phase 2Active, not recruiting

Episodic Migraine

NCT06625060

Phase 2Recruiting

Cervical Dystonia

NCT06937931

Q4 2028

Phase 3Recruiting

Moderate to Severe Glabellar Lines

NCT07435428

Q1 2029

PreclinicalRecruiting

Spasticity

NCT04752774

Clinical

Trials by Indication[1]

Moderate to Severe Glabellar Lines2 trials

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants

Active, not recruiting· Ipsen logo

Ipsen·Phase 3·NCT07427797·309 enrolled

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled and Open-label Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants, and to Evaluate the Long-term Efficacy and Safety of Repeat Doses of IPN10200 in the Same Indication

Recruiting· Ipsen logo

Ipsen·Phase 3·NCT07435428·1,300 enrolled

Moderate to Severe Upper Facial Lines1 trial

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults

Active, not recruiting· Ipsen logo

Ipsen·Preclinical·NCT04821089·727 enrolled

Episodic Migraine1 trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

Active, not recruiting· Ipsen logo

Ipsen·Phase 2·NCT06625060·670 enrolled

Cervical Dystonia1 trial

A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

Recruiting· Ipsen logo

Ipsen·Phase 2·NCT06937931·132 enrolled

Spasticity1 trial

An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.

Recruiting· Ipsen logo

Ipsen·Preclinical·NCT04752774·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for IPN10200. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPN10200 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPN10200. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Ipsen

Related News